Package Insert approved by the South African Medicines Regulatory Authority (MCC)

Apter D, Borsos A et al.  2003.  Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.  the European Journal of Contraception and Reproductive Health Care, 8:37-51

Boschitsch E, Skarabis H et al. 2000.  The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.  The European Journal of Contraception and Reproductive Health Care, 5(suppl 3):34-40

Foidart J.-M.  2002.  Clinical experiences with *.  Gynaecology Forum, vol 7, no. 1

Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V, Doll R et al.  2008.  Ovarian cancer and oral contraceptives:  collaborative reanalysis of data from 45 epidemiological studies including 23 257 women with ovarian cancer and 87303 controls. Lancet. Jan 26;371(9609):303-314

 Qureshi B. 1998.  Recent medical news.  Oral contraceptives and health.  Journal of the Royal Society of Health.  Dec;118(6)329-330

 The ESHRE Capri Workshop Group.  2005.  Noncontraceptive health benefits of combined oral contraception.  Human Reproduction Update, Vol.11, No.5, 513-525.

 Farrow A, Hull M.G.R et al. 2002.  Prolonged use of oral contraception before a planned pregnancy is associated with a decrease risk of delayed conception.  Human Reproduction Vol.17, No.10, 2754-2761.

 Black A, Francoeur D et al.  2004.  Canadian Contraception Consensus. SOCG Clinical practice guidelines No. 143 - Part 2 of 3, March 2004.

Foidart J.-M. 2000.  The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects.  The European Journal of Contraception and Reproductive Health Care; 5(Suppl 4):25-33

Guillebaud J. 2001. 3rd ed. Contraception your questions answered.